FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

Published

News published by Insmed Incorporated concerning ARIKAYCE, administered by the Lamira® Nebulizer System based on eFlow® Technology platform.

 

Read the press release

Back to overview